Stocks and Investing
Stocks and Investing
Mon, April 3, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sat, April 1, 2023
[ 12:00 AM ] - WOPRAI
Fri, March 31, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Elemer Piros Reiterated (ATAI) at Strong Buy and Held Target at $15 on, Mar 31st, 2023
Elemer Piros of EF Hutton, Reiterated "Atai Life Sciences N.V." (ATAI) at Strong Buy and Held Target at $15 on, Mar 31st, 2023.
Elemer has made no other calls on ATAI in the last 4 months.
There are 3 other peers that have a rating on ATAI. Out of the 3 peers that are also analyzing ATAI, 0 agree with Elemer's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Elemer
- Judah Frommer of "Credit Suisse" Reiterated at Buy and Held Target at $9 on, Monday, March 27th, 2023
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Thursday, January 19th, 2023
- Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Decreased Target to $10 on, Monday, January 9th, 2023
Contributing Sources